미국의 임상 종양 차세대 시퀀싱 시장 규모, 점유율, 동향 분석 보고서 : 워크플로우별, 기술별, 용도별, 최종 용도별, 부문별 예측(2025-2030년)

U.S. Clinical Oncology Next Generation Sequencing Market Growth & Trends:

The U.S. clinical oncology next-generation sequencing market size is expected to reach USD 500.4 million by 2030, expanding at a CAGR of 15.04% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is expected to increase at a significant rate during the forecast period from 2023 to 2030 owing to the increasing competition among the industry players, technological advances in the field and decreasing costs for genetic sequencing.

The increasing market competition and the launch of innovative solutions based on next generation sequencing in the oncology field are expected to fuel market growth over the forecast period. For instance, in February 2023, Exact Sciences Corp., a cancer screening and diagnostic testing company, introduced the therapy selection test -OncoExTra in the U.S. It is a next-generation sequencing-based genomic test to help in cancer care. It helps in understanding and characterizing cancer tumors. Moreover, to gain a competitive edge in the industry, companies are collaborating and focusing on advancing in the next generation sequencing. For instance, in January 2020, the two key players operating in the market, Illumina, Inc and F. Hoffmann-La Roche Ltd, signed a 15-year agreement to discover NGS's potential to transform cancer detection, diagnosis, risk prediction, treatment, and monitoring.

Moreover, various articles and studies are being published on the use of NGS in oncology and cancer treatments. For instance, in June 2023, the Lancet published an article on real-world outcomes and the usefulness of NGS testing in cancer patients. Furthermore, in June 2023, the American Society Of Clinical Oncology published a study on the clinical impact of NGS tests for managing advanced cancer in the U.S. Such studies help researchers and clinicians increase awareness and knowledge about the use of NGS for cancer treatments.

Furthermore, the growth of the clinical oncology next-generation sequencing market during the forecast period is expected to witness growth due to reduced sequencing costs. The costs of NGS can be reduced by increasing parallel sequencing and running multiple flow cells to increase sequencing capacity without raising the costs associated with it. These factors are anticipated to boost the market demand over the forecast period in the U.S.

U.S. Clinical Oncology Next Generation Sequencing Market Report Highlights:

• NGS sequencing accounted for the largest revenue share of 56.65% in 2024 based on the workflow segment. The dominance of the segments is due to the increasing number of cancer sequencing projects and technological advances in the field.
• Based on the technology, targeted sequencing & resequencing dominated the market with a revenue share of 72.51% in 2024. This can be attributed to the rising use of targeted panels and their efficiency in identifying cancer tumors.
• Based on the application, the screening segment dominated the U.S. clinical oncology NGS market with a revenue share of 79.94% in 2024, owing to the growing prevalence of cancer disorder across the country.
• Based on the end-use, the laboratories segment accounted for the largest share of 63.47% in the U.S. clinical oncology NGS market in 2024. This dominance of the segment is due to the rising research and development activities for cancer treatment.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Technology
  • 1.2.2. Workflow
  • 1.2.3. Application
  • 1.2.4. End Use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Reduction in costs for genetic sequencing
    • 3.2.1.2. Advances in the field of personalized medicine
    • 3.2.1.3. Increase in prevalence of cancer
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of computational efficiency for data management
• 3.3. U.S. Clinical Oncology NGS Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Clinical Oncology Next Generation Sequencing Market: Technology Estimates & Trend Analysis

• 4.1. Technology Segment Dashboard
• 4.2. U.S. Clinical Oncology NGS Market Technology Movement Analysis
• 4.3. U.S. Clinical Oncology NGS Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 4.4. Whole Genome Sequencing
  • 4.4.1. Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
• 4.5. Whole Exome Sequencing
  • 4.5.1. Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
• 4.6. Targeted Sequencing & Resequencing
  • 4.6.1. Targeted Sequencing & Resequencing Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Clinical Oncology Next Generation Sequencing Market: Workflow Estimates & Trend Analysis

• 5.1. Workflow Segment Dashboard
• 5.2. U.S. Clinical Oncology NGS Market Workflow Movement Analysis
• 5.3. U.S. Clinical Oncology NGS Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
• 5.4. NGS Pre-Sequencing
  • 5.4.1. NGS Pre-Sequencing Market, 2018 - 2030 (USD Million)
• 5.5. NGS Sequencing
  • 5.5.1. NGS Sequencing Market, 2018 - 2030 (USD Million)
• 5.6. NGS Data Analysis
  • 5.6.1. NGS Data Analysis Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Clinical Oncology Next Generation Sequencing Market: Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. U.S. Clinical Oncology NGS Market Application Movement Analysis
• 6.3. U.S. Clinical Oncology NGS Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Screening
  • 6.4.1. Screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 6.4.2. Sporadic Cancer
    • 6.4.2.1. Sporadic cancer screening U.S. clinical Oncology NGS Market ,2018 - 2030 (USD Million)
  • 6.4.3. Inherited cancer
    • 6.4.3.1. Inherited cancer screening U.S. clinical Oncology NGS Market ,2018 - 2030 (USD Million)
• 6.5. Companion Diagnostics
  • 6.5.1. Companion diagnostics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
• 6.6. Other Diagnostics
  • 6.6.1. Other diagnostics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Clinical Oncology Next Generation Sequencing Market: End Use Estimates & Trend Analysis

• 7.1. End Use Segment Dashboard
• 7.2. U.S. Clinical Oncology NGS Market End Use Movement Analysis
• 7.3. U.S. Clinical Oncology NGS Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Hospitals
  • 7.4.1. Hospitals U.S. Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
• 7.5. Clinics
  • 7.5.1. Clinics U.S. Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
• 7.6. Laboratories
  • 7.6.1. Laboratories U.S. Clinical Oncology NGS Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Profiles/Listing
  • 8.3.1. Illumina, Inc.
    • 8.3.1.1. Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Product Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Thermo Fisher Scientific Inc.
    • 8.3.2.1. Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Product Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. F. Hoffmann-La Roche Ltd
    • 8.3.3.1. Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Product Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Agilent Technologies, Inc.
    • 8.3.4.1. Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Product Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Myriad Genetics, Inc.
    • 8.3.5.1. Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Product Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Beijing Genomics Institute (BGI)
    • 8.3.6.1. Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Product Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. QIAGEN
    • 8.3.7.1. Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Product Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Perkin Elmer, Inc.
    • 8.3.8.1. Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Product Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. PacBio
    • 8.3.9.1. Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Product Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Oxford Nanopore Technologies
    • 8.3.10.1. Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Product Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. PerkinElmer Inc
    • 8.3.11.1. Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Product Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Macrogen, Inc
    • 8.3.12.1. Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Product Benchmarking
    • 8.3.12.4. Strategic Initiatives